Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma

Gaetano Corazzelli, Francesco Angrilli, Alfonso D'Arco, Felicetto Ferrara, Pellegrino Musto, Attilio Guarini, Maria Christina Cox, Caterina Stelitano, Sergio Storti, Emilio Iannitto, Simona Falorio, Catello Califano, Alfonso Amore, Manuela Arcamone, Rosaria De Filippi, Antonio Pinto

Research output: Contribution to journalArticle

Abstract

The management of patients with Hodgkin lymphoma (HL) recurring after stem cell transplantation (SCT) and multiply relapsed disease remains challenging. We report on 41 such patients who received bendamustine hydrochloride, a bifunctional mechlorethamine derivative mechanistically unrelated to traditional alkylators, after a median of four prior chemotherapy lines, including SCT in 85% of cases. Bendamustine was given at doses of 90-120 mg/m2 every 21 or 28 d. At first assessment (2-4 cycles), the overall response rate (ORR) was 78% with 12 (29%) complete (CR) and 20 (49%) partial responses (PR). Upon treatment prolongation to 6-8 courses, 40% of PRs progressed, yielding a final ORR of 58% with 31% of CRs. Eight patients (two CRs, six PRs) were subsequently allotransplanted. Median progression-free and overall survival exceeded 11 and 21 months respectively; complete responders displayed a median disease-free survival above 9 months with a relapse rate of only 30%. Outcomes were independent of disease chemosensitivity, previous transplant and bendamustine dose-intensity. No life-threatening or unexpected adverse events occurred. Within the limits of a retrospective analysis and schedule heterogeneity, these results appear very encouraging and prompt prospective trials to confirm bendamustine as a valuable option in the palliative setting and in cytoreductive strategies before allotransplantation.

Original languageEnglish
Pages (from-to)207-215
Number of pages9
JournalBritish Journal of Haematology
Volume160
Issue number2
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Hodgkin Disease
Safety
Stem Cell Transplantation
Disease-Free Survival
Mechlorethamine
Alkylating Agents
Therapeutics
Appointments and Schedules
Transplants
Recurrence
Drug Therapy
Bendamustine Hydrochloride

Keywords

  • Alkylating agents
  • Bendamustine
  • Hodgkin lymphoma
  • Salvage chemotherapy
  • Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. / Corazzelli, Gaetano; Angrilli, Francesco; D'Arco, Alfonso; Ferrara, Felicetto; Musto, Pellegrino; Guarini, Attilio; Cox, Maria Christina; Stelitano, Caterina; Storti, Sergio; Iannitto, Emilio; Falorio, Simona; Califano, Catello; Amore, Alfonso; Arcamone, Manuela; De Filippi, Rosaria; Pinto, Antonio.

In: British Journal of Haematology, Vol. 160, No. 2, 01.2013, p. 207-215.

Research output: Contribution to journalArticle

Corazzelli, G, Angrilli, F, D'Arco, A, Ferrara, F, Musto, P, Guarini, A, Cox, MC, Stelitano, C, Storti, S, Iannitto, E, Falorio, S, Califano, C, Amore, A, Arcamone, M, De Filippi, R & Pinto, A 2013, 'Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma', British Journal of Haematology, vol. 160, no. 2, pp. 207-215. https://doi.org/10.1111/bjh.12120
Corazzelli, Gaetano ; Angrilli, Francesco ; D'Arco, Alfonso ; Ferrara, Felicetto ; Musto, Pellegrino ; Guarini, Attilio ; Cox, Maria Christina ; Stelitano, Caterina ; Storti, Sergio ; Iannitto, Emilio ; Falorio, Simona ; Califano, Catello ; Amore, Alfonso ; Arcamone, Manuela ; De Filippi, Rosaria ; Pinto, Antonio. / Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. In: British Journal of Haematology. 2013 ; Vol. 160, No. 2. pp. 207-215.
@article{8bc72e4bb8f64d1d8b38d8069e04906e,
title = "Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma",
abstract = "The management of patients with Hodgkin lymphoma (HL) recurring after stem cell transplantation (SCT) and multiply relapsed disease remains challenging. We report on 41 such patients who received bendamustine hydrochloride, a bifunctional mechlorethamine derivative mechanistically unrelated to traditional alkylators, after a median of four prior chemotherapy lines, including SCT in 85{\%} of cases. Bendamustine was given at doses of 90-120 mg/m2 every 21 or 28 d. At first assessment (2-4 cycles), the overall response rate (ORR) was 78{\%} with 12 (29{\%}) complete (CR) and 20 (49{\%}) partial responses (PR). Upon treatment prolongation to 6-8 courses, 40{\%} of PRs progressed, yielding a final ORR of 58{\%} with 31{\%} of CRs. Eight patients (two CRs, six PRs) were subsequently allotransplanted. Median progression-free and overall survival exceeded 11 and 21 months respectively; complete responders displayed a median disease-free survival above 9 months with a relapse rate of only 30{\%}. Outcomes were independent of disease chemosensitivity, previous transplant and bendamustine dose-intensity. No life-threatening or unexpected adverse events occurred. Within the limits of a retrospective analysis and schedule heterogeneity, these results appear very encouraging and prompt prospective trials to confirm bendamustine as a valuable option in the palliative setting and in cytoreductive strategies before allotransplantation.",
keywords = "Alkylating agents, Bendamustine, Hodgkin lymphoma, Salvage chemotherapy, Transplantation",
author = "Gaetano Corazzelli and Francesco Angrilli and Alfonso D'Arco and Felicetto Ferrara and Pellegrino Musto and Attilio Guarini and Cox, {Maria Christina} and Caterina Stelitano and Sergio Storti and Emilio Iannitto and Simona Falorio and Catello Califano and Alfonso Amore and Manuela Arcamone and {De Filippi}, Rosaria and Antonio Pinto",
year = "2013",
month = "1",
doi = "10.1111/bjh.12120",
language = "English",
volume = "160",
pages = "207--215",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma

AU - Corazzelli, Gaetano

AU - Angrilli, Francesco

AU - D'Arco, Alfonso

AU - Ferrara, Felicetto

AU - Musto, Pellegrino

AU - Guarini, Attilio

AU - Cox, Maria Christina

AU - Stelitano, Caterina

AU - Storti, Sergio

AU - Iannitto, Emilio

AU - Falorio, Simona

AU - Califano, Catello

AU - Amore, Alfonso

AU - Arcamone, Manuela

AU - De Filippi, Rosaria

AU - Pinto, Antonio

PY - 2013/1

Y1 - 2013/1

N2 - The management of patients with Hodgkin lymphoma (HL) recurring after stem cell transplantation (SCT) and multiply relapsed disease remains challenging. We report on 41 such patients who received bendamustine hydrochloride, a bifunctional mechlorethamine derivative mechanistically unrelated to traditional alkylators, after a median of four prior chemotherapy lines, including SCT in 85% of cases. Bendamustine was given at doses of 90-120 mg/m2 every 21 or 28 d. At first assessment (2-4 cycles), the overall response rate (ORR) was 78% with 12 (29%) complete (CR) and 20 (49%) partial responses (PR). Upon treatment prolongation to 6-8 courses, 40% of PRs progressed, yielding a final ORR of 58% with 31% of CRs. Eight patients (two CRs, six PRs) were subsequently allotransplanted. Median progression-free and overall survival exceeded 11 and 21 months respectively; complete responders displayed a median disease-free survival above 9 months with a relapse rate of only 30%. Outcomes were independent of disease chemosensitivity, previous transplant and bendamustine dose-intensity. No life-threatening or unexpected adverse events occurred. Within the limits of a retrospective analysis and schedule heterogeneity, these results appear very encouraging and prompt prospective trials to confirm bendamustine as a valuable option in the palliative setting and in cytoreductive strategies before allotransplantation.

AB - The management of patients with Hodgkin lymphoma (HL) recurring after stem cell transplantation (SCT) and multiply relapsed disease remains challenging. We report on 41 such patients who received bendamustine hydrochloride, a bifunctional mechlorethamine derivative mechanistically unrelated to traditional alkylators, after a median of four prior chemotherapy lines, including SCT in 85% of cases. Bendamustine was given at doses of 90-120 mg/m2 every 21 or 28 d. At first assessment (2-4 cycles), the overall response rate (ORR) was 78% with 12 (29%) complete (CR) and 20 (49%) partial responses (PR). Upon treatment prolongation to 6-8 courses, 40% of PRs progressed, yielding a final ORR of 58% with 31% of CRs. Eight patients (two CRs, six PRs) were subsequently allotransplanted. Median progression-free and overall survival exceeded 11 and 21 months respectively; complete responders displayed a median disease-free survival above 9 months with a relapse rate of only 30%. Outcomes were independent of disease chemosensitivity, previous transplant and bendamustine dose-intensity. No life-threatening or unexpected adverse events occurred. Within the limits of a retrospective analysis and schedule heterogeneity, these results appear very encouraging and prompt prospective trials to confirm bendamustine as a valuable option in the palliative setting and in cytoreductive strategies before allotransplantation.

KW - Alkylating agents

KW - Bendamustine

KW - Hodgkin lymphoma

KW - Salvage chemotherapy

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84872275912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872275912&partnerID=8YFLogxK

U2 - 10.1111/bjh.12120

DO - 10.1111/bjh.12120

M3 - Article

C2 - 23167437

AN - SCOPUS:84872275912

VL - 160

SP - 207

EP - 215

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -